Clinical Trial Update: Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients (INMUNOEND)

View source ↗

Summary

A clinical trial investigating whether CMV-specific immune reconstitution after termination of letermovir prophylaxis influences the risk of late cytomegaloviru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Letermovir (letermovir)

Snippet

Sponsor: Maimónides Biomedical Research Institute of Córdoba | Conditions: Cytomegalovirus Cell Mediated Immunity, Stem Cell Transplantation, Hematopoietic | Status: NOT_YET_RECRUITING